Autophagy Process in Parkinson's Disease Depends on Mutations in the GBA1 and LRRK2 Genes
- PMID: 40388077
- DOI: 10.1007/s10528-025-11125-z
Autophagy Process in Parkinson's Disease Depends on Mutations in the GBA1 and LRRK2 Genes
Abstract
Parkinson's disease (PD) is a common neurodegenerative disorder characterized by the loss of dopaminergic neurons and abnormal aggregation of the alpha-synuclein protein. Disruption of the autophagy-lysosomal pathway is closely associated with PD pathogenesis. Here, using western-blot analysis we assessed the level of autophagy-related proteins, including phosphorylated mTOR (p-mTOR), phosphorylated RPS6 (p-RPS6), beclin-1 (BECN1), LC3B, p62, and cathepsin D (CTSD) in macrophages derived from peripheral blood mononuclear cells (PBMC-derived macrophages) of GBA1-PD (p.N370S/N, p.L444P/N), LRRK2-PD (p.G2019S/N), idiopathic PD (iPD) patients, and healthy controls. Our findings revealed mutation-specific disruptions in autophagy pathways among PD patients. In p.N370S-GBA1-PD, PBMC-derived macrophages exhibited elevated levels of p-RPS6, BECN1, LC3B-II and decreased mature form of CTSD levels suggesting more active mTOR-dependent autophagy initiation alongside potential autophagosome accumulation that may lead to downregulation of lysosomal degradation. p.L444P-GBA1-PD PBMC-derived macrophages showed increased levels of p-RPS6 and BECN1, coupled with decreased p62 levels and stable mature form of CTSD and LC3B-II, indicative of enhanced autophagy flux driven by mTOR activity without evident lysosomal dysfunction. In p.G2019S-LRRK2-PD patients, PBMC-derived macrophages demonstrated elevated p-RPS6, LC3B-II, and mature CTSD levels, alongside reduced p62 levels. These changes suggest higher basal autophagosome abundance in steady-state autophagy and turnover, potentially driven by lysosomal alterations rather than direct mTOR dysregulation. These mutation-dependent differences highlight distinct autophagy dynamics in GBA1-PD and LRRK2-PD, underscoring the critical role of genetic mutations in modulating PD pathogenesis. Our results emphasize the necessity for subtype-specific therapeutic strategies targeting autophagy and other mTOR-regulated pathways to address the heterogeneity of PD mechanisms.
Keywords: GBA1; LRRK2; Autophagy; PBMC-derived macrophages; Parkinson’s disease; mTOR.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Competing Interests: The authors declare no competing financial interests. Ethical Approval: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Pavlov First Saint-Petersburg State Medical University (Protocol number: 244, Approval Date: 25 January 2021). Consent to Participate: Informed consent was obtained from all individual participants included in the study. Consent to Publication: Not applicable.
Similar articles
-
The Effect of p.G2019S Mutation in the LRRK2 Gene on the Activity of Lysosomal Hydrolases and the Clinical Features of Parkinson's Disease Associated with p.N370S Mutation in the GBA1 Gene.J Integr Neurosci. 2024 Jan 16;23(1):16. doi: 10.31083/j.jin2301016. J Integr Neurosci. 2024. PMID: 38287861
-
Constitutive silencing of LRRK2 kinase activity leads to early glucocerebrosidase deregulation and late impairment of autophagy in vivo.Neurobiol Dis. 2021 Nov;159:105487. doi: 10.1016/j.nbd.2021.105487. Epub 2021 Aug 20. Neurobiol Dis. 2021. PMID: 34419621
-
Acid ceramidase involved in pathogenic cascade leading to accumulation of α-synuclein in iPSC model of GBA1-associated Parkinson's disease.Hum Mol Genet. 2023 May 18;32(11):1888-1900. doi: 10.1093/hmg/ddad025. Hum Mol Genet. 2023. PMID: 36752535 Free PMC article.
-
Lysosomal Pathogenesis of Parkinson's Disease: Insights From LRRK2 and GBA1 Rodent Models.Neurotherapeutics. 2023 Jan;20(1):127-139. doi: 10.1007/s13311-022-01290-z. Epub 2022 Sep 9. Neurotherapeutics. 2023. PMID: 36085537 Free PMC article. Review.
-
"LRRK2: Autophagy and Lysosomal Activity".Front Neurosci. 2020 May 25;14:498. doi: 10.3389/fnins.2020.00498. eCollection 2020. Front Neurosci. 2020. PMID: 32523507 Free PMC article. Review.
Cited by
-
Cathepsins in Neurological Diseases.Int J Mol Sci. 2025 Aug 15;26(16):7886. doi: 10.3390/ijms26167886. Int J Mol Sci. 2025. PMID: 40869205 Free PMC article. Review.
References
-
- Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R (2004) Mutations in the glucocerebrosidase gene and Parkinson’s disease in Ashkenazi Jews. N Engl J Med 351:1972–1977. https://doi.org/10.1056/NEJMoa033277 - DOI - PubMed
-
- Albanese F, Mercatelli D, Finetti L et al (2021) Constitutive silencing of LRRK2 kinase activity leads to early glucocerebrosidase deregulation and late impairment of autophagy in vivo. Neurobiol Dis 159:105487. https://doi.org/10.1016/j.nbd.2021.105487 - DOI - PubMed
-
- Bjørkøy G, Lamark T, Brech A et al (2005) p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J Cell Biol. https://doi.org/10.1083/jcb.200507002 - DOI - PubMed - PMC
-
- Bogetofte H, Ryan BJ, Jensen P et al (2023) Post-translational proteomics platform identifies neurite outgrowth impairments in Parkinson’s disease GBA-N370S dopamine neurons. Cell Rep. https://doi.org/10.1016/j.celrep.2023.112180 - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous